|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aprea Therapeutics, Inc. (APRE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
20,990,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, a mutated gene in cancer. Co.'s main product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia. Co. is conducting several trials in hematologic malignancy indications, including a trial of eprenetapopt with azacitidine for frontline treatment of TP53 mutant MDS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
16,730 |
16,730 |
26,827 |
114,327 |
| Total Buy Value |
$121,961 |
$121,961 |
$158,917 |
$218,541 |
| Total People Bought |
4 |
4 |
4 |
5 |
| Total Buy Transactions |
4 |
4 |
6 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Korbel Gregory Alan |
SVP, Chief Operating Officer |
• – – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
24,300 |
45,762 |
|
- |
|
| Duey Marc |
Director |
– • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,995 |
157,899 |
|
- |
|
| Schade Christian S |
Director |
– • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
32,400 |
259,246 |
|
- |
|
| Gilad Oren |
President, CEO |
• – – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
101,300 |
330,314 |
|
- |
|
| Henneman John B III |
Director |
– • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,995 |
15,605 |
|
- |
|
| Pamukcu Rifat |
Director |
– • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,995 |
7,862 |
|
- |
|
| Coiante Scott M |
SVP, Chief Financial Officer |
• – – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
60,800 |
145,065 |
|
- |
|
| Coiante Scott M |
SVP, Chief Financial Officer |
• • – |
2022-06-03 |
4 |
D |
$0.81 |
$28,404 |
D/D |
(35,284) |
84,265 |
|
- |
|
| Korbel Gregory Alan |
SVP, Chief Operating Officer |
• • – |
2022-06-03 |
4 |
D |
$0.81 |
$6,754 |
D/D |
(8,390) |
21,462 |
|
- |
|
| Schade Christian S |
Chairman & CEO |
• • – |
2022-06-03 |
4 |
D |
$0.81 |
$52,945 |
D/D |
(65,770) |
226,846 |
|
- |
|
| Attar Eyal C. |
SVP, Chief Medical Officer |
• • – |
2022-06-03 |
4 |
D |
$0.81 |
$26,297 |
D/D |
(32,667) |
57,233 |
|
- |
|
| Schade Christian S |
Chairman & CEO |
• • – |
2022-05-18 |
4 |
B |
$0.64 |
$24,124 |
D/D |
37,500 |
292,616 |
2.81 |
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2022-05-18 |
4 |
B |
$0.71 |
$35,500 |
D/D |
50,000 |
318,580 |
2.39 |
- |
|
| Duey Marc |
|
– • – |
2022-05-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
439 |
|
- |
|
| Duey Marc |
|
– • – |
2022-05-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
151,904 |
|
- |
|
| Pamukcu Rifat |
|
– • – |
2022-05-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,299 |
|
- |
|
| Pamukcu Rifat |
|
– • – |
2022-05-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,867 |
|
- |
|
| Gilad Oren |
President |
• • – |
2022-05-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
229,014 |
|
- |
|
| Abrahmsen Lars B. |
SVP, Chief Scientific Officer |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
24,700 |
43,700 |
|
- |
|
| Schade Christian S |
Chairman & CEO |
• • – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
100,100 |
255,116 |
|
- |
|
| Coiante Scott M |
SVP, Chief Financial Officer |
• • – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
42,900 |
119,549 |
|
- |
|
| Korbel Gregory Alan |
SVP, Chief Business Officer |
• • – |
2022-03-10 |
4 |
D |
$1.82 |
$3,620 |
D/D |
(1,989) |
29,852 |
|
- |
|
| Korbel Gregory Alan |
SVP, Chief Business Officer |
• • – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
31,841 |
|
- |
|
| Attar Eyal C. |
SVP, Chief Medical Officer |
• • – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
42,900 |
89,900 |
|
- |
|
| Attar Eyal C. |
SVP, Chief Medical Officer |
• – – |
2022-02-28 |
4 |
AS |
$1.73 |
$62,280 |
D/D |
(36,000) |
47,000 |
|
- |
|
126 Records found
|
|
Page 2 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
